ALTHOUGH GREAT PROGRESS has been made in the prevention and therapy of acute gastric mucosal lesions (AGML), AGML is still recognized as an important cause of gastrointestinal bleeding (21) . Moreover, the pathogenesis of AGML has yet to be fully elucidated. AGML is frequently observed in clinical situations, such as stress-induced gastric ischemia-reperfusion (I/R) injury, a major cause of AGML. Low blood flow with subsequent reflow induces the generation of reactive oxygen species (ROS), such as superoxide radicals, hydroxyl radicals, and peroxynitrite. These ROS attack and damage the gastric mucosa leading to the formation of AGMLs (19, 22, 23) . I/R injuries continue to be important clinical problems in addition to their contribution to the formation of AGMLs (7) . In the gastrointestinal tract, I/R injuries are associated with significant morbidity and mortality during the course of hemorrhagic shock, abdominal aortic aneurysm repair, ischemic bowel disease, and necrotizing enterocolitis (7, 8, 25) . It also remains unclear whether the pathophysiological mechanisms associated with I/R-induced AGML are also involved in the generation of stress-related gastritis (7, 19, 21) .
Peroxisome proliferator-activated receptor-␥ (PPAR␥) is one of the nuclear receptors involved in adipocyte differentiation and insulin sensitivity (9, 12) . PPAR␥ is activated by several ligands including 15-deoxy-⌬ 12,14 -prostaglandin J 2 and thiazolidinedione derivatives, such as troglitazone, pioglitazone, and rosiglitazone (BRL-49653) that are used as oral anti-hyperglycemic agents in the therapy of diabetes mellitus (5, 9) . Recently, our group and others (3, 14, 20, 26) reported that PPAR␥ plays an anti-inflammatory role in intestinal inflammation associated with administration of either dextran sodium sulfate or trinitrobenzene sulfonic acid and exposure to I/R injury.
On the basis of these observations, we investigated whether PPAR␥ had a similar protective effect in the AGML induced by I/R. Specifically, we assessed PPAR␥ ligands such as BRL-49653, pioglitazone, or troglitazone in an I/R-induced AGML model involving clamping the celiac artery that is commonly used by many investigators for assessing such responses (15, 16) . Furthermore, to clarify the role of endogenous PPAR␥ in the stomach, we also examined the I/Rinduced AGML model in heterozygous PPAR␥-deficient (ϩ/Ϫ) mice (13) . Results from these investigations provide strong evidence supporting an important role for endogenous PPAR␥ activity in the pathogenesis of I/R injury in the stomach.
MATERIALS AND METHODS
Animals. BALB/c mice were purchased from Charles River Japan (Yokohama, Japan). PPAR␥-deficient mice were generated by our group and are previously described (13) . Because homozygous PPAR␥-deficient embryos (Ϫ/Ϫ) die due to placental dysfunction, we used heterozygous PPAR␥-deficient mice (ϩ/Ϫ) in this study as previously described (14) .
Reagents. The PPAR␥-specific agonist BRL-49653 was a kind gift of SmithKlineBeecham (Tokyo, Japan). Pioglitazone was kindly provided by Takeda (Osaka, Japan). Troglitazone was kindly provided by Sankyo (Tokyo, Japan). All other chemicals were of reagent grade.
I/R-induced AGML. All animal experiments were performed in accordance with The Guidelines for Animal Experimentation of the Yokohama City University School of Medicine. Adult male BALB/c mice, heterozygous PPAR␥-deficient mice (ϩ/Ϫ), or wild-type control mice (ϩ/ϩ) (weighing 20 -25 g) were fasted for 12-14 h before all experiments, except for free access to water. I/R of the stomach was produced by the occlusion of the celiac artery as previously described (15, 16, 22, 23) . Briefly, under pentobarbital sodium (50 mg/kg ip) anesthesia, the celiac artery was occluded with a small clamp (Sugita standard aneurysm clip, holding force: 140 -150 g; Mizuho Ikakogyo, Tokyo, Japan) for 30 min. Reperfusion was achieved by removing the clamp for 60 min. Sham-operated animals underwent the same surgical procedure without clamping. BRL-49653 (1-10 mg/kg ip), pioglitazone (10 mg/kg ip), and troglitazone (30 mg/kg ip) were administered 15 min before ischemia. Mice were killed, and tissue samples were collected.
Evaluation of injury. A picture of the whole stomach was obtained and analyzed with a digital imaging analyzer (model FAS3; Toyobo, Osaka, Japan). Areas of macroscopic damage associated with the AGML (recognized as reddish bleeding areas by the computer system) were measured and summed together as the total injured areas (mm 2 ) using the National Institutes of Health imaging system. Evaluation of the macroscopic stomach damage was performed according to a method described previously (23) .
Histological analysis. Tissue samples were fixed in 3.7% formaldehyde-PBS overnight at 4°C. Samples were dehydrated and embedded in paraffin. Three-micrometer sections were stained with hematoxylin and eosin.
Immunohistochemical staining of PPAR␥, ICAM-1, inducible nitric oxide synthase, and nitrotyrosine. Expression and localization of PPAR␥ in tissues was detected by standard immunohistochemical techniques using the anti-PPAR␥ polyclonal antibody (Cayman Chemical, Ann Arbor, MI) on paraffin sections. The vectastain ABC kit (Vector Laboratories, Burlingame, CA) was used with the 3,3Ј-diaminobenzidine substrate kit (Vector Laboratories) according to the manufacturer's instructions for detection as previously described (11, 14) .
Alterations of ICAM-1, inducible nitric oxide synthase (iNOS) expression, and nitrotyrosine deposition in tissues were detected by standard immunohistochemical techniques using either anti-ICAM-1, anti-iNOS polyclonal antibody (Santa Cruz Biotech, Santa Cruz, CA), or anti-nitrotyrosine antibody (mouse anti-nitrotyrosine, clone HM11; Zymed Laboratories) on paraffin sections. The vectastain ABC kit (Vector Laboratories) was used with the 3,3Ј-diaminobenzidine substrate kit (Vector Laboratories) according to the manufacturer's instructions for detection.
Terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling staining. Alterations of apoptotic cells in the tissues was detected by standard immunohistochemical techniques using the DeadEnd fluorometric terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL) System (Promega, Madison, WI)
RNA protection assay for TNF-␣ expression. RNA protection assays for quantification of TNF-␣ expression were performed according to a method described previously (6) . Briefly, RNA was extracted from tissues, and 10 g of total sample RNA was hybridized with a 32 P-labeled anti-sense RNA probe. The RiboQuant Multi-Probe RNase Protection Assay System (Pharmingen, San Diego, CA) was used according to the manufacturer's instructions. Quantification was performed by using a Phosphorimager (Bio-Rad, Hercules, CA) and was normalized to expression of a housekeeping gene (GAPDH).
Statistical analysis. All results are expressed as means Ϯ SE. Statistical comparisons were made by using either Student's t-test or Scheffé's method after ANOVA. Results were considered significantly different at P Ͻ 0.05.
RESULTS

Effect of PPAR␥ ligands on I/R-induced AGML.
Previous studies have established that PPAR␥ is present in the stomach, albeit at levels that are much less than in the small and large intestines (14) . Therefore, to investigate whether PPAR␥ was protective in gastric I/R, the effect of a specific PPAR␥ ligand was examined. BALB/c mice were subjected to I/R injury of the stomach in either the presence or absence of the PPAR␥ ligand BRL-49653. Macroscopic damage was observed in the stomachs of the group subjected to I/R. The total area of damage was significantly diminished by treatment with BRL-49653 in a dose-dependent manner (Fig. 1) . Compared with sham-operated animals not subjected to I/R, hemorrhage and a loss of villi were observed in the I/R-injured stomach as defined microscopically (Fig. 2, I /R). Treatment with BRL-49653 dramatically diminished the microscopic alterations observed in the I/R-stomach (Fig. 2, I /R ϩ BRL). Furthermore, apoptotic cells, a characteristic feature of the AGML lesion, were observed in the I/R-injured stomach as defined by the levels of green fluorescence observed by using a fluorometric TUNEL system method (Fig. 3B) . Treatment with BRL-49653 (10 mg/kg) dramatically diminished the proportion of apoptotic cells in the I/R-stomach (Fig. 3C ). These data demonstrate that the PPAR␥ agonist BRL-49653 can inhibit AGML formation induced by I/R.
To confirm the effect of BRL-49653 is dependent on PPAR␥ pathway, we used other PPAR␥ agonists (pioglitazone and troglitazone) on the AGML model. Treatment with pioglitazone (10 mg/kg) and troglitazone (30 mg/kg) showed the significant inhibition of tissue damages in stomach induced by I/R. The efficacy of troglitazone was much weaker than those of BRL-49653 and pioglitazone (Fig. 4) . These results clearly indicate that the inhibition of the formation of AGML by PPAR␥ agonists is dependent on the PPAR␥ pathway.
Expression of ICAM-1 and iNOS in stomach tissue. Adhesion molecules play an important role in the transendothelial migration of leukocytes into inflammatory tissues (14, 19, 22, 25) . Therefore, the expression of ICAM-1 in stomach tissues was investigated by immunohistochemistry after the I/R procedure. When BALB/c mice were exposed to I/R, strong positive staining for ICAM-1 expression was detected in the stomach (Fig. 5A ). This positive staining was markedly diminished by treatment with BRL-49653 (Fig. 5B ) at a dose of 10 mg/kg, suggesting that activation of PPAR␥ prevented the upregulation of this adhesion molecule.
It is well known that increased expression of iNOS is directly associated with the degree of inflammation (10) . Therefore, we also investigated the expression of iNOS in the stomach in response to I/R. Increased expression of iNOS was detected in I/R stomach (Fig. 5C ), which was diminished by treatment with BRL-49653 at a dose of 10 mg/kg (Fig. 5D) . These studies show that activation of PPAR␥ leads to downregulation of several pathways involved in amplifying the inflammatory response associated with I/R injury in the stomach.
Nitrotyrosine formation in stomach tissue. It is well known that nitric oxide and superoxide radicals react with each other to form peroxynitrite, which attacks tyrosine residues in proteins to form nitrotyrosine (18, 24) . Therefore, nitrotyrosine formation is indicative of the presence of ROS. Formation of nitrotyrosine was observed in the I/R-injured stomach as defined microscopically (Fig. 6, I /R). Treatment with BRL-49653 dramatically diminished the levels of detectable nitrotyrosine in the I/R-stomach (Fig. 6 , I/R ϩ BRL). These results indicate that the PPAR␥ ligand BRL-49653 can reduce the injury associated with the formation of free radicals that occurs during acute injury by I/R.
PPAR␥ ligand inhibits the increase in mRNA for TNF-␣ in stomach.
It has been reported that I/R-induced injury is associated with the production of various proinflammatory cytokines including TNF-␣ (14, 17) . Therefore, we measured the levels of mRNA for TNF-␣ in stomach tissues in response to I/R in either the presence or absence of the PPAR␥ ligand. Increased mRNA levels for TNF-␣ could be detected in I/Rstomach in control mice, and these were significantly diminished by treatment with BRL-49653 (Fig. 7) . These results show that activation of PPAR␥ leads to downregulation of a proinflammatory cytokine associated with amplification of the inflammatory response during I/R injury in stomach.
Effects of PPAR␥ deficiency on AGML induced by I/R. To directly confirm a role for endogenous PPAR␥ activity in the protection against gastric I/R injury, the response of heterozygous PPAR␥-deficient mice in the formation of AGML induced by I/R was compared with wild-type mice (ϩ/ϩ) of the same strain (13, 14) . Notably, messenger RNA and protein levels of PPAR␥ in PPAR␥-deficient mice (ϩ/Ϫ) within the gastrointestinal tract were significantly lower than those observed in wild-type mice (ϩ/ϩ) (14) . As can be seen in Fig.  8A , a greater degree of injury was observed in PPAR␥-deficient mice (ϩ/Ϫ), compared with wild-type mice (ϩ/ϩ), after the I/R procedure as defined by both macroscopic and microscopic analyses (data not shown). To confirm and quantify these results, tissue damage was directly measured by using an image analysis system. A significant increase in the total area of injury was observed in I/R stomach from PPAR␥-deficient mice compared with the wild-type mice (Fig. 8B) . These results strongly indicate that endogenous PPAR␥ activity plays a direct role in the protection from injury related to I/R.
In the presence of diminished levels of PPAR␥ as observed in heterozygous PPAR␥-deficient mice, the AGML associated with I/R was exacerbated. Despite this diminution in PPAR␥ levels and increased susceptibility to I/R injury, BRL-49653 (10 mg/kg) was able to inhibit tissue damage in the heterozy- (Fig. 8C ) and quantitative assessment of the damaged area (Fig. 8D) . These results indicate that activation of even reduced levels of PPAR␥ in tissues is sufficient to provide some protection against I/R injury of the stomach.
Localization of PPAR␥ in stomach. To clarify the localization of PPAR␥ within stomach, we performed immunohistochemical analysis of PPAR␥ protein. As shown in Fig. 9 , the expression of PPAR␥ was observed in mucosal epithelial cells and parietal cells. PPAR␥ observed in both epithelial and parietal cells in stomach might be potential targets for PPAR␥ agonists.
DISCUSSION
In this study, we demonstrated the dramatic protective effects of PPAR␥ agonists, BRL-49653, pioglitazone, and troglitazone on the AGML associated with an I/R injury. We observed that BRL-49653 significantly diminished the total areas of mucosal damage in a dose-dependent fashion after I/R. Other PPAR␥ agonists, pioglitazone and troglitazone, also showed the same protective effects against the AGML. These results suggest a specific role for PPAR␥ in protecting against this type of tissue injury. We further defined the protective effect of endogenous PPAR␥ activity in AGML induced by I/R through an examination of PPAR␥-deficient mice. Results from these investigations provide strong evidence in support of an important role for endogenous PPAR␥ activity in protecting from I/R injury in the stomach. In particular, these results strongly suggest that PPAR␥ plays an intrinsic protective role in the stomach against I/R-induced injury as we have observed with other forms of severe, acute mucosal inflammation (14) . These findings support the existence of an endogenous antiinflammatory pathway in the stomach that is mediated by PPAR␥. Actually, expression of PPAR␥ protein is observed both in mucosal epithelial cells and parietal cells. PPAR␥ in both epithelial and parietal cells in stomach might be potential targets for PPAR␥ agonists.
It should be noted that the PPAR␥ levels within the gastrointestinal tract are higher than that observed in other organs, although the level of PPAR␥ in stomach is much lower than those of small intestine and colon (2, 14) . The reason for these differences is not apparent. However, the low levels observed in the stomach may predispose this organ to AGML. Nonetheless, despite its low levels, PPAR␥ activation in the stomach does provide endogenous protection against I/R, as shown here, and possibly other injurious events and is of high enough content that it could possibly be engaged by pharmacological activation as predicted by our result with the mice heterozygous for PPAR␥ expression. The relatively high levels of expression of PPAR␥ in the small intestine and colon may assist in suppressing inflammation in these organs associated with I/R and other forms of tissue injury (3, 14, 20, 26) . Whether the relatively high levels of PPAR␥ in the small and large intestine is due, in part, to the increased bacterial burden present in these organs, at least in the colon, is unknown. However, these results suggest that this indeed may be case, because PPAR␥ may be the regulated by the intestinal microflora (4) . If so, this may be particularly important for the pathogenesis of inflammatory bowel disease.
Through the use of the PPAR␥ agonist BRL-49653, we have also established that one possible mechanism by which PPAR␥ activation leads to protection against I/R-related injury is through inhibition of expression of proinflammatory cytokines (e.g., TNF-␣), inflammatory mediators (e.g., iNOS), adhesion molecules (e.g., ICAM-1), and apoptosis. In our previous study (14) , we also reported that a PPAR␥ ligand inhibited the expression of ICAM-1 protein and TNF-␣ mRNA in intestinal I/R injury via inhibition of NF-B activation. As TNF-␣ and other cytokines and adhesion molecules are downstream targets of NF-B (1), this implies a similar role for PPAR␥-mediated inhibition of NF-B activation in gastric tissues. Further investigation of this hypothesis is required to clarify whether this and/or other molecular targets of PPAR␥ are involved in this protection.
Furthermore, activation of PPAR␥ might inhibit the formation of ROS. We observed strong staining for nitrotyrosine products in the tissue sections of mice exposed to I/R injury compared with those of normal, nonexposed mice. However, inhibition of nitrotyrosine formation was observed in the tissue sections of mice treated with BRL-49653. These results indicate that formation of ROS is induced by the I/R procedure and, in turn, inhibited by treatment with BRL-49653. Thus inhibition of the formation of injurious ROS products may be a major mechanism by which PPAR␥ agonists provide protective from I/R.
In this study, we have also demonstrated that the AGML induced by I/R in PPAR␥-deficient mice was more severe than that observed in wild-type mice. Our results clearly indicate that an endogenous PPAR␥ activation pathway plays a direct role in protection from injury related to I/R. Decreased areas of injury were also observed in the heterozygous PPAR␥-deficient mice exposed to the I/R procedure and treated with the PPAR␥ ligand compared with heterozygous PPAR␥-deficient mice without PPAR␥ ligand treatment. These results clearly show the potency of PPAR␥ in this pathophysiological context and raises the possibility that pharmacological manipulation of PPAR␥ may be successful in affording protection despite the reduced levels of PPAR␥ in the stomach.
In conclusion, an endogenous anti-inflammatory pathway involving PPAR␥ is present in the stomach such that activation of PPAR␥ provides potent protection against the injury associated with gastric I/R injury. Activation of PPAR␥ in the stomach diminishes the increase in proinflammatory cytokine expression associated with I/R, likely via an NF-B-mediated pathway. Findings of this study open up the new possibility for PPAR␥ agonist therapy in AGML and potentially, other forms of tissue injury in the stomach that involve similar pathophysiological mechanisms.
